The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin
Open accessAbstract
ErbB2 is a transmembrane tyrosine kinase whose surface overexpression is linked to tumorigenesis and poor prognosis in breast cancer patients. Two models have emerged that account for the high surface distribution of ErbB2. In one model, the surface pool is dynamic and governed by a balance between endocytosis and recycling, whereas in the other it is retained, static, and excluded from endocytosis. These models have contrasting implications for how ErbB2 exerts its biological function and how cancer therapies might down-regulate surface ErbB2, such as the antibody trastuzumab (Herceptin) or the Hsp90 inhibitor geldanamycin. Little is known, however, about how these treatments affect ErbB2 endocytic trafficking. To investigate this issue, we examined breast carcinoma cells by immunofluorescence and quantitative immunoelectron microscopy and developed imaging and trafficking kinetics assays using cell surface fluorescence quenching. Surprisingly, trastuzumab does not influence ErbB2 distribution but instead recycles passively with internalized ErbB2. By contrast, geldanamycin down-regulates surface ErbB2 through improved degradative sorting in endosomes exclusively rather than through increased endocytosis. These results reveal substantial dynamism in the surface ErbB2 pool and clearly demonstrate the significance of endosomal sorting in the maintenance of ErbB2 surface distribution, a critical feature of its biological function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 2×
“In human breast cancer, the ErbB2 gene is amplified and overexpressed in 25% of cases and is associated with poor prognosis (Slamon et al., 1987).”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“In 1998 the FDA approved a recombinant humanized form of one such antibody, trastuzumab, for the treatment of ErbB2- overexpressing breast cancer (Cobleigh et al., 1999; Slamon et al., 2001).”
BackgroundUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“ErbB2 (Her2) is a transmembrane tyrosine kinase belonging to a surface receptor family that includes epidernal growth factor receptor (EGFR; Yarden and Sliwkowski, 2001 ).”
BackgroundSelf-citationInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“In vivo, studies in mice suggest that the host immune response might contribute substantially to the antitumor effect (Clynes et al., 2000).”
BackgroundCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Self-citationerb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · cited 2×
“A different class of mAbs instead disrupts ligandactivated mitogenic signaling (Klapper et al., 1997; Agus et al., 2002).”
BackgroundResultSelf-citationSlot, J. W., Geuze, H. J., Gigengack, S., Lienhard, G. E., & James, D. E. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.123 · Cited by 862
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Biology of HER2 and Its Importance in Breast Cancer
Yarden, Y. (2001) · Oncology · doi:10.1159/000055396 · Cited by 737
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Self-citationMolecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5251 · Cited by 454
FENDLY, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., & Ullrich, A. (1990) · PubMed · Cited by 403
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. (1985) · Cell · doi:10.1016/s0092-8674(85)80050-7 · Cited by 400
The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis.
Wiley, H. S., & Cunningham, D. D. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34709-4 · Cited by 391
Longva, K. E., Blystad, F. D., Stang, E., Larsen, A. M., Johannessen, L. E., & Madshus, I. H. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200106056 · Cited by 386
Cuello, M. A., Ettenberg, S. A., Clark, A. S., Keane, M., Posner, R. H., Nau, M. M., Dennis, P. A., & Lipkowitz, S. (2001) · PubMed · Cited by 370
Bilayered Clathrin Coats on Endosomal Vacuoles Are Involved in Protein Sorting toward Lysosomes
Sachse, M., Urbé, S., Oorschot, V., Strous, G. J., & Klumperman, J. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-10-0525 · Cited by 321
Self-citationMechanism of action of anti-HER2 monoclonal antibodies
Baselga, J., & Albanell, J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s35 · Cited by 265
Citri, A. (2002) · The EMBO Journal · doi:10.1093/emboj/21.10.2407 · Cited by 233
Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization.
Lund, K. A., Opresko, L. K., Starbuck, C., Walsh, B. J., & Wiley, H. S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55456-9 · Cited by 210
Association with Membrane Protrusions Makes ErbB2 an Internalization-resistant Receptor
Hommelgaard, A. M., Lerdrup, M., & van Deurs, B. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-08-0596 · Cited by 210
Wang, Z., Zhang, L., Yeung, T. K., & Chen, X. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.5.1621 · Cited by 181
Klapper, L. N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y., & Sela, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201029 · Cited by 174
Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. A. (2003) · PubMed · Cited by 159
Hurwitz, E., Stancovski, I., Sela, M., & Yarden, Y. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3353 · Cited by 148
Sorkin, A. D., Fiore, P. P. D., & Carpenter, G. (1993) · PubMed · Cited by 139
Harwerth, I. M., Wels, W. S., Marte, B. M., & Hynes, N. E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42160-6 · Cited by 123
Lin, S. X. H., Mallet, W. G., Huang, A. Y., & Maxfield, F. R. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-07-0497 · Cited by 113
Kumar, R., Shepard, H. M., & Mendelsohn, J. M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.2.979 · Cited by 111
Kelley, R. F., O'Connell, M. P., Carter, P. M., Presta, L. G., Eigenbrot, C. W., Covarrubias, M., Snedecor, B., Bourell, J. H., & Vetterlein, D. (1992) · Biochemistry · doi:10.1021/bi00139a003 · Cited by 96
Self-citationp185HER2 signal transduction in breast cancer cells
Scott, G. K., Dodson, J. M., Montgomery, P. A., Johnson, R. M., Sarup, J. C., Wong, W., Ullrich, A., Shepard, H. M., & Benz, C. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98683-7 · Cited by 87
Geldanamycin Induces ErbB-2 Degradation by Proteolytic Fragmentation
Tikhomirov, O., & Carpenter, G. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003114200 · Cited by 75
Role of Cytoplasmic Domain Serines in Intracellular Trafficking of Furin
Schapiro, F. B., Soe, T. T., Mallet, W. G., & Maxfield, F. R. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-09-0653 · Cited by 41
The p185 erbB2 protein is localized on cell organelles involved in cell motility
Potter, C. R. D., & Quatacker, J. R. (1993) · Clinical & Experimental Metastasis · doi:10.1007/bf00054936 · Cited by 32
Cited by
Nanoparticle-mediated cellular response is size-dependent
Jiang, W., Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.30 · Cited by 2,776
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Self-citationMonoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Metadata
- Authors
- Austin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H.
- Venue
- Molecular Biology of the Cell
- Published
- 2004-12
- Volume
- 15
- Issue
- 12
- Pages
- 5268-5282
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- OpenAlex
- W2141346487
- Cited by
- 496
- References
- 45
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.